InvestSMART

Firebrick Pharma Limited (ASX: FRE) - Announcements

- Current share price for FRE : $0.030

ASX company news and announcements for Firebrick Pharma Limited (FRE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Firebrick Pharma Limited (FRE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Firebrick Pharma Limited (FRE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Firebrick Pharma Limited (FRE)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$9 Nasodine Patent Granted in Malaysia 25 May 2022 8:34AM $0.385 $0.030 fallen by 92.21%
$9 Firebrick Appoints Dr Richard Treagus as Director 25 May 2022 8:25AM $0.385 $0.030 fallen by 92.21%
$9 Firebrick starts Phase 3 common cold trial of Nasodine 3 May 2022 1:22PM $0.405 $0.030 fallen by 92.59%
$9 March 2022 Quarterly Activity Report & Appendix 4C 26 Apr 2022 5:07PM $0.455 $0.030 fallen by 93.41%
$9 Firebrick starts COVID-19 trial of Nasodine 26 Apr 2022 9:59AM $0.460 $0.030 fallen by 93.48%
$9 Investor Presentation - Euroz Hartleys Rottnest Conference 11 Mar 2022 12:26PM $0.415 $0.030 fallen by 92.77%
$9 Investor Presentation - Euroz Hartleys Rottnest Conference 11 Mar 2022 12:19PM $0.415 $0.030 fallen by 92.77%
$9 FRE to file appeal seeking immediate approval of Nasodine 1 Mar 2022 9:44AM $0.450 $0.030 fallen by 93.33%
$9 Nasodine US Patent Granted for COVID-19 17 Feb 2022 9:42AM $0.470 $0.030 fallen by 93.62%
$9 31 December Interim Financial Report & Appendix 4D 11 Feb 2022 4:31PM $0.500 $0.030 fallen by 94%
$9 Nasodine in vitro and pilot human COVID-19 studies published 10 Feb 2022 9:30AM $0.480 $0.030 fallen by 93.75%
$9 Nasodine COVID-19 trial receives SAHPRA approval 1 Feb 2022 9:50AM $0.650 $0.030 fallen by 95.38%
$9 Becoming a substantial holder - Stephen Goodall 25 Jan 2022 1:20PM $0.002 $0.030 risen by 1,400%
$9 Becoming a substantial holder - Peter Molloy 25 Jan 2022 1:19PM $0.002 $0.030 risen by 1,400%
$9 Becoming a substantial holder - Firebrick Pharma 25 Jan 2022 1:19PM $0.002 $0.030 risen by 1,400%
$9 Initial Director's Interest Notice - Stephen Goodall 25 Jan 2022 1:18PM $0.002 $0.030 risen by 1,400%
$9 Initial Director's Interest Notice - Peter Molloy 25 Jan 2022 1:18PM $0.002 $0.030 risen by 1,400%
$9 Initial Director's Interest Notice - Phyllis Gardner 25 Jan 2022 1:17PM $0.002 $0.030 risen by 1,400%
$9 Pre-Quotation Disclosure 25 Jan 2022 12:13PM $0.002 $0.030 risen by 1,400%
$9 Top 20 Holders 25 Jan 2022 12:12PM $0.002 $0.030 risen by 1,400%
$9 Distribution Schedule 25 Jan 2022 12:10PM $0.002 $0.030 risen by 1,400%
$9 Securities Trading Policy 25 Jan 2022 12:10PM $0.002 $0.030 risen by 1,400%
$9 Corporate Governance Statement 25 Jan 2022 12:08PM $0.002 $0.030 risen by 1,400%
$9 Employee Incentive Plan 25 Jan 2022 12:07PM $0.002 $0.030 risen by 1,400%
$9 Annual Report 30 June 2021 25 Jan 2022 12:06PM $0.002 $0.030 risen by 1,400%

301 - 325 of 530 results

Page 13 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.